Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vB_EcoS-K12
- Development stage
- Preclinical
01
Overview
vB_EcoS-K12 is a bacteriophage that targets and infects susceptible *Escherichia coli* isolates, particularly those associated with drug-resistant bacterial infections. As a lytic phage, it functions by binding to specific receptors on the bacterial cell surface, injecting its genetic material, replicating within the host, and ultimately lysing the bacterial cell to release progeny phages. vB_EcoS-K12 is utilized as a therapeutic adjunct matched to patient-specific resistant isolates via precision antimicrobial platforms, such as Precise Health's matching service, to restore or enhance antibacterial efficacy against multi-drug resistant pathogens.
- Other names
- vB_EcoS-K12
Beyond the preview
Go deeper on vB_EcoS-K12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vB_EcoS-K12.